Cargando…

How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality

Pharmacoeconomic data are widely used along drug life cycle for supporting decision-making processes on research and development, pricing and reimbursement, and market access. In this context, the incremental cost-effectiveness ratio (ICER) is the gold standard of either cost-effectiveness analyses...

Descripción completa

Detalles Bibliográficos
Autor principal: Russo, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768610/
https://www.ncbi.nlm.nih.gov/pubmed/36628320
http://dx.doi.org/10.33393/grhta.2022.2350
_version_ 1784854208921468928
author Russo, Pierluigi
author_facet Russo, Pierluigi
author_sort Russo, Pierluigi
collection PubMed
description Pharmacoeconomic data are widely used along drug life cycle for supporting decision-making processes on research and development, pricing and reimbursement, and market access. In this context, the incremental cost-effectiveness ratio (ICER) is the gold standard of either cost-effectiveness analyses (CEAs) or cost-utility analyses (CUAs) of pharmaceuticals and health technologies. However, the widespread use of confidentiality clauses in the agreements between pharmaceutical companies and the payers may affect the reliability of ICER value based on transparent price. The aim of this article is to evaluate a case study and simulate the impact of price confidentiality and other managed-entry agreement conditions on the ICER value. The case study was conducted selecting a CEA submitted to the Health Economic Evaluations Office of the Italian Medicines Agency by the pharmaceutical company, which specifically compared two alternative options reimbursed by the Italian NHS using confidential managed-entry agreements. So, a real model was used to collect the output of ICERs generated by the simulation model, considering price inputs of alternative options ranging from the transparent prices to the confidential net price. The simulation showed that price confidentiality may affect the estimated value of the ICER of a new medicine and, consequently, its interpretation. From a different point of view, the published ICER values may also give a completely false economic evidence if non-disclosure agreements are not taken into account. A proposal for editors of pharmacoeconomic journals to improve reliability of CEA is also discussed.
format Online
Article
Text
id pubmed-9768610
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AboutScience
record_format MEDLINE/PubMed
spelling pubmed-97686102023-01-09 How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality Russo, Pierluigi Glob Reg Health Technol Assess Point of View Pharmacoeconomic data are widely used along drug life cycle for supporting decision-making processes on research and development, pricing and reimbursement, and market access. In this context, the incremental cost-effectiveness ratio (ICER) is the gold standard of either cost-effectiveness analyses (CEAs) or cost-utility analyses (CUAs) of pharmaceuticals and health technologies. However, the widespread use of confidentiality clauses in the agreements between pharmaceutical companies and the payers may affect the reliability of ICER value based on transparent price. The aim of this article is to evaluate a case study and simulate the impact of price confidentiality and other managed-entry agreement conditions on the ICER value. The case study was conducted selecting a CEA submitted to the Health Economic Evaluations Office of the Italian Medicines Agency by the pharmaceutical company, which specifically compared two alternative options reimbursed by the Italian NHS using confidential managed-entry agreements. So, a real model was used to collect the output of ICERs generated by the simulation model, considering price inputs of alternative options ranging from the transparent prices to the confidential net price. The simulation showed that price confidentiality may affect the estimated value of the ICER of a new medicine and, consequently, its interpretation. From a different point of view, the published ICER values may also give a completely false economic evidence if non-disclosure agreements are not taken into account. A proposal for editors of pharmacoeconomic journals to improve reliability of CEA is also discussed. AboutScience 2022-02-25 /pmc/articles/PMC9768610/ /pubmed/36628320 http://dx.doi.org/10.33393/grhta.2022.2350 Text en https://creativecommons.org/licenses/by-nc/4.0/Global & Regional Health Technology Assessment - ISSN 2283-5733 - www.aboutscience.eu/grhta (http://www.aboutscience.eu/grhta) © 2022 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu (http://www.aboutscience.eu)
spellingShingle Point of View
Russo, Pierluigi
How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
title How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
title_full How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
title_fullStr How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
title_full_unstemmed How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
title_short How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
title_sort how reliable are icer’s results published in current pharmacoeconomic literature? the controversial issue of price confidentiality
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768610/
https://www.ncbi.nlm.nih.gov/pubmed/36628320
http://dx.doi.org/10.33393/grhta.2022.2350
work_keys_str_mv AT russopierluigi howreliableareicersresultspublishedincurrentpharmacoeconomicliteraturethecontroversialissueofpriceconfidentiality